ReviewClinical cardiology2002
Anticoagulants for atrial fibrillation: why is the treatment rate so low?
Review in Clinical cardiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Self-monitoring and self-management of oral anticoagulation.The Cochrane database of systematic reviews · 2016Pooled it
- What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire.Journal of thrombosis and thrombolysis · 2006Trial
- Knowledge, attitude, and practice regarding atrial fibrillation among primary care physicians: the potential role of postgraduate training.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2021Article
- Internet Search Trends and Regional Mortality Tendencies: The Case of Oral Anticoagulants and Stroke.Arquivos brasileiros de cardiologia · 2020Article
- Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.Journal of managed care & specialty pharmacy · 2018Observational
- Stroke Prevention in Atrial Fibrillation in the Very Elderly: Anticoagulant Therapy Is No Longer a Sin.Journal of the American Heart Association · 2017Article
- Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.Health and quality of life outcomes · 2017Article
- A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals.BMJ open · 2014Article
- Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians.Thrombosis journal · 2014Article
- [New oral anticoagulants: who really needs them?].Der Internist · 2014Article
- Treatment patterns associated with stroke prevention in patients with atrial fibrillation in three major cities in the People's Republic of china.International journal of general medicine · 2013Article
- [New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].Zeitschrift fur Gerontologie und Geriatrie · 2012Review
- Do physician outcome judgments and judgment biases contribute to inappropriate use of treatments? Study protocol.Implementation science : IS · 2007Article
- Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy.Internal and emergency medicine · 2007Article
- Oral heparin: status review.Thrombosis journal · 2006Article
- Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.Postgraduate medical journal · 2005Review
- Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.Heart (British Cardiac Society) · 2005Article
- Hepatic findings in long-term clinical trials of ximelagatran.Drug safety · 2005Review
- Anticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatran.Current controlled trials in cardiovascular medicine · 2004Article
- Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records.BMC clinical pharmacology · 2004Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of atrial fibrillation (AF) is increasing in many countries along with aging demographics. Atrial fibrillation is clearly associated with an increased rate of stroke. Numerous large clinical trials have shown that dose-adjusted warfarin can reduce the stroke rate in these patients, particularly in the elderly, and clear guidelines for the use of anticoagulants in such patients have been published. However, many studies show that treatment rates remain disappointingly low (< or = 50%). Numerous barriers to the use of dose-adjusted warfarin exist, including practical, patient-, physician-, and healthcare system-related barriers. These include the complex pharmacokinetics of warfarin, the need for continuous prothrombin time monitoring and dose adjustments, bleeding events, noncompliance, drug interactions, and increased costs of monitoring and therapy. Possible solutions to this problem are discussed and include improved patient and physician education, the use of anticoagulation clinics, new approaches to AF, and potential treatment improvements through use of newer anticoagulants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.